Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?

Deepesh P. Lad · Pankaj Malhotra ·
Subhash Varma

Received: 25 March 2012 / Accepted: 31 August 2012 / Published online: 9 October 2012
© Indian Society of Haematology & Transfusion Medicine 2012

Abstract There have been remarkable advances in our understanding of the biology and therapeutics of chronic lymphocytic leukemia. B cell receptor signaling and micro-environment in CLL biology have been the most modern areas of research. In CLL therapeutics, we have come a long way from alkylating agents to chemo-immunotherapy. Despite this there remain significant lacunae in the disease biology that has hindered our quest to achieve the ultimate in CLL: Cure. This review aims to summarize the past, present and future in the biology and treatment of CLL.

Keywords Chronic lymphocytic leukemia · Biology · Treatment · Review

Introduction

Cinderella of All Leukemias

For decades chronic lymphocytic leukemia (CLL) received little attention. Largely because it has a prolonged course, many persons afflicted by CLL live a relatively normal life and eventually die of causes unrelated to CLL. Despite this seemingly unexciting background, the task of understanding pathogenesis and designing new therapies in CLL has challenged and fascinated clinical investigators almost continuously over the past half century. The reason for this fascination is the extreme variability in the clinical course

of patients with CLL. Currently CLL is receiving increasing attention from biologists and clinicians. Characteristics of this disease have helped to define relationships between antigenic stimulation and malignant transformation as well as shed light on association of lymphoid tumors and autoimmunity. CLL is a good model for studying basic and translational research pertaining to investigations and treatment of B cell chronic lymphoproliferative disorders. The factors that make CLL a good model for research are its high population prevalence, ease of accessibility of malignant cells for study and that most patients being asymptomatic have long disease specific survival. Therefore CLL has been called as the “Cinderella” of all leukemias [1].

Ontogenesis in CLL

Antigen-activated naive B-cells differentiate into centroblasts. These introduce somatic hyper mutations (SHM) to increase affinity to antigen; into the immunoglobulin variable segment (IgV) gene during the clonal expansion in the dark zone of the germinal center of lymph nodes. This is a T cell dependent process. A parallel T cell independent process bypassing IgV hyper mutation (unmutated) also exists. Centroblasts then differentiate into centrocytes and move to the light zone. Here B cells with improved antigen-binding are selected. A subset of centrocytes finally differentiates into memory/marginal zone B cells or plasma cells. The germinal centre reaction involves the risk of oncogenic transformation at several steps of differentiation, resulting in the development of different lymphoma subtypes. The cell of origin in CLL is presumed to be a memory/marginal zone B cell irrespective of whether it has undergone SHM (mutated CLL) or no SHM (unmutated CLL). These antigen experienced cells may then be

D. P. Lad · P. Malhotra (✉) · S. Varma
Department of Internal Medicine, Post Graduate Institute
of Medical Education and Research, Chandigarh, India
e-mail: malhotrapankaj@hotmail.com

Fig. 1 Microenvironmental interactions of the malignant B cell with the stromal cells, effector T-cells and T-regulatory cells in the peripheral blood, lymph-node and bone marrow. Key events occurring in the microenvironment include 1. stimulation of the BCR 2.

BCR signaling 3. Interactions with stromal cells 4. Interactions with T-effector and T-regulatory cells. Potential sites of therapeutic targets are also shown

continuously activated through persisting antigen [2]. They acquire genetic alterations that lead to outgrowth of clones with a monoclonal B lymphocytosis (MBL) phenotype. Some ultimately undergo oncogenic transformation to CLL. Six percent of the normal elderly population develops MBL. MBL is precursor to CLL in 1–2 % cases [3]. Recent studies have questioned the existence of MBL as a distinct entity. It may be appropriate to consider MBL as early stage CLL as both are similar in terms of biologic, genetic and clinical behavior [4].

In unmutated CLL because V-gene mutations do not occur, repetitive interactions between antigens and poly-reactive B cell receptors (BCR) of the initially selected clone promote clonal growth. In mutated CLL, V-gene mutations develop that can abrogate the polyreactivity of the BCR and thereby alter their ability to bind the original antigen or autoantigen (“clonal ignorance”). Alternatively, these mutated cells become anergic owing to excessive B cell-receptor stimulation because of the acquisition of more avid receptors [5]. Differences in the signals received through the BCR and other receptors determine the extent of clonal expansion.

Microenvironment in CLL (Fig. 1)

The CLL microenvironment is a complex system of many cell types which are involved in active molecular cross talk providing a functional support to the CLL cells. These accessory cells include endothelial cells and their precursors, pericytes, smooth muscle cells, fibroblasts, neutrophils, mast cells, T, B and Natural killer lymphocytes, and antigen presenting cells like dendritic cells and macrophages. The microenvironment is an essential, integral part of any cancer [6].

B cell receptor signaling is the principal event that occurs in the CLL microenvironment. The BCR is a key survival molecule for normal B cells and most B cell malignancies. BCR is composed of a membrane associated immunoglobulin, noncovalently associated with a disulfide linked CD79a and CD79b heterodimer. CD79a and CD79b serve as the receptors of primary signal transduction. Initial antigen binding leads to the formation of a signalosome, a complex of kinases and scaffold proteins. The triggering event is phosphorylation of the immunoreceptor tyrosine based activation motifs (ITAMs) of CD79a and CD79b by

SRC family kinase LYN. The BCR signal is further propagated by SYK via B cell linker protein and downstream signals of Brutons tyrosine kinase (BTK) and phospholipase C (PLC). PLC generates secondary messengers, inositol triphosphate and diacylglycerol (DAG), which leads to activation of protein kinase C (PKC). PKC further activates nuclear factor κ B (NF- κ B), mitogen activated protein kinases (MAPK). Finally these all signals are modulated to determine proliferation, survival, and migration via transcriptional modulation and phosphorylation (Mcl-1, Cyclins, MYC) [7].

Bone marrow stromal cells viz nurse like cells (NLC) and follicular dendritic cells (FDC) are key regulators of normal B lymphopoiesis. These synthesize several cytokines including colony stimulating factors, IL6, IL7, IL10 and TGF β and stem cell factor thereby regulating CLL B cells. Various adhesion integrins like VLA-4 and its ligand VCAM-1 are involved in adhesion of stromal cells to CLL B cells. NLCs protect CLL cells from apoptosis through CXCL12 (stromal cell derived factor SDF-1), B-cell activating factor (BAFF), CD31 and plexinB1. FDC also rescue CLL B-cells from apoptosis in vitro by up-regulating anti-apoptotic Bcl-2 family protein Mcl1 [8].

Within the LN the largest contributor to CLL survival known to date is the T helper cell, via cell–cell contact with B-CLL cell. In normal B cell development antigen engaged B cells migrate toward Th cells by chemotaxis forming B-T conjugates in pseudofollicles or proliferation centers. There occurs crosslinking and signaling via CD40 (expressed on B cell) and CD40L (CD154 expressed on Th cell). This interaction is critical to induce and sustain B cell response. Various cytokines are released during this T–B interaction to further enhance the co-operation. CLL B-cells produce and express ligands and receptors for many survival cytokines viz. IL-2, IL-4, IL-8, TNF α , IFN α , and VEGF. They promote their own survival via autocrine and paracrine pathways [9].

Despite all the advancements in the knowledge of the biology of CLL, few unanswered questions remain. The nature of the antigen triggering the entire process, the

reasons for low expression of BCR, the reasons for somatic mutation only in some CLL cells and the mechanisms of immune surveillance escape, all remain an enigma.

Prognostic Markers in CLL

The heterogeneous clinical profile of CLL patients has lead many researchers to propose several prognostic markers over the past few decades. Currently there is problem of plenty when it comes to choosing the right prognostic marker at the right time [10]. Rai [11] and Binet [12] staging have been the cornerstone of prognosticating patients for decades (Table 1). However there are inherent inadequacies in these traditional markers. Binet/Rai staging does not distinguish between autoimmune cytopenias or marrow infiltration as a cause of anemia or thrombocytopenia and that results in classifying a patient as having stage C or high risk disease. Recently it has been identified that autoimmune cytopenias do not confer a poor prognosis in CLL [13]. Also it cannot predict indolent or aggressive nature of CLL. Lymphocyte doubling time has also been used for years; however it requires at least three patient visits over a period for its estimation [14]. This can be uncomfortable for patients wishing to know their prognosis at first visit. β -2 microglobulin is a nonspecific but reliable marker and is used for most lymphomas and leukemias [15]. Recently cytogenetics by FISH has helped to identify certain subsets in CLL with 17p deletion and 11q deletion which perform poorly and may be indications for early intervention [16, 17]. Whether these would be of any use even in asymptomatic patients still remains controversial. IgVH gene mutation status [18], though a good marker, has been restricted to research labs due to non availability. CD38 [19] and ZAP70 [20] are used currently as surrogate markers for IgVH mutation status. Both have not lived up to the expectations. CD38 expression changes during course of the disease, while ZAP70 has suffered from lack of reproducibility between labs. There is some data to suggest that Absolute Treg cell count may serve as a reliable prognostic marker in the near future [21]. It is important to counsel

Table 1 Modified Rai and Binet staging for CLL

	Modified Rai	Binet	Survival
Lymphocytosis	Low risk	A	>10 years
		<3 involved groups	
Lymphocytosis + nodal involvement $\pm$ organomegaly	Intermediate risk	B	5–9 years
		$\geq$ 3 involved groups	
Lymphocytosis + anemia/thrombocytopenia	High risk	C	2–5 years
	Hb < 11g/dl	Hb < 10gm/dl	
	Platelet < 100,000/ μ l	Platelet < 100,000/ μ l	

patients regarding the availability of prognostic markers and its application. They should be informed that currently there are no indications for early treatment in an asymptomatic patient outside of a clinical trial. It should be stressed that statistics are for a population and not an individual. Many patients desire such information; others decline such testing to avoid stress of knowing unfavorable markers without ability to effectively intervene.

When to Treat?

This is the most important question in CLL management. International working group guidelines have become the standard for decision regarding starting therapy [22] (Table 2) and also for response assessment. It is important that only patients with active or progressive disease be put on treatment. Treatment of all other patients is generally not indicated outside a clinical trial.

Treatment Options

The treatment goals have changed over the decades from palliation in the 1970s, to complete remission in 2000, to progression free survival and minimal residual disease negative CR in the last decade. The treatment armamentarium has also expanded over the years from alkylating agents in 1960s, to purine analogues in 1980s and chemoimmunotherapy in 2000.

First Weapon: Alkylating agents

Chlorambucil, the first of the alkylating agents was synthesized in 1953. The electrophilic alkyl group of chlorambucil covalently binds to cellular nucleophilic sites resulting in DNA cross linkages and cytotoxicity. It was first shown to be effective in CLL in 1956 [23]. A meta-analysis showed no survival benefit for combination chemotherapy (CHOP/CVP) over chlorambucil [24]. Chlorambucil and prednisolone was the frontline therapy for decades. It is still the combination of choice in frail or patients with comorbidities. It has low toxicity profile, is cheap and has convenient dosing. However it has very low

CR rates. There is a theoretical risk of secondary leukemia and of myelodysplasia. Bendamustine, another alkylating agent with additional benzimidazole group was synthesized in 1960. However it received FDA approval for CLL only in 2008, after it was demonstrated to have higher response rates, longer remissions and progression free survival in comparison to chlorambucil [25]. It has a different mechanism of action than chlorambucil, apoptosis is one, however the exact mechanism remains unknown.

Second Weapon: Purine Analogues

Fludarabine (F) was synthesized as a rational process to develop more active analogues of cytarabine. It has multiple mechanisms of action. It is converted to F-Ara-ATP inside the cell where it competes with dATP for incorporation in DNA leading to chain termination. It also inhibits DNA replication by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase. It has also been found to reduce number of Treg cells. F has higher ORR and CR-rate in comparison to chlorambucil. However no difference for PFS, OS could be demonstrated in the initial study [26]. A long term follow-up of the same study showed that survival curves begin to separate in favor of F at 6 years [27]. These benefits may not be valid in elderly populations, where the superiority of purine analogues over chlorambucil could not be demonstrated [28]. When F was compared with F-cyclophosphamide (FC) combination, there was significantly higher OR (95.3 vs. 84.1 %), CR (20.3 vs. 8.6 %) and longer PFS in the FC arm. But no difference in the overall survival could be demonstrated. It became the first line standard from 2006 [29]. The optimum dosing and duration of all treatments including chlorambucil for survival benefit needs to be determined [30].

Third Weapon: Monoclonal Antibodies

The prognosis had not substantially improved over time and there was a need for therapies with impact on overall survival. The time was right for use of monoclonal antibodies in CLL. They had already proved to be effective in other lymphomas. Their mode of action through complement mediated cytotoxicity and antibody dependent cellular toxicity (ADCC) is different. It was the reason for their entry in clinical trials in CLL. Results of initial trials with single agent rituximab in relapsed/refractory CLL were disappointing with no CRs but only partial responses [31, 32]. Subsequent studies of single agent rituximab as first line therapy showed that therapy-naïve patients fared better with rituximab than previously treated patients. Though complete responses were rare in this trial, maintenance therapy improved the outcome relative to a single course of treatment [33]. The exact mechanism and reason why rituximab

Table 2 Indications of treatment in CLL (from most common to least common)

- 1 Progressive marrow failure, anemia $\pm$ thrombocytopenia
- 2 Autoimmune cytopenias poorly responsive to treatment
- 3 Significant constitutional symptoms
- 4 Massive nodes (10 cm)/progressive/symptomatic lymphadenopathy
- 5 Massive/progressive/symptomatic splenomegaly
- 6 Lymphocyte doubling time $\leq$ 6 months

(antiCD20) is effective in CLL which has low CD20 expression still remains unknown. CD52 expression in CLL is 45 times that of CD20. It was only matter of time that alemtuzumab (antiCD52) was explored in phase II studies in previously treated CLL. Significant objective response rates ranging from 33 to 70 % were documented with median duration of response exceeding 12 months [34, 35]. In another study median overall survival was 16 months for all patients, extending up to 24 months for responders. Median survival among responders was not reached till the end of the study [36]. This led to study of single agent alemtuzumab as first line. Result were an impressive 87 % OR, 19 % CR and 68 % PR [37]. The currently available evidence suggests an OS, CR and PFS benefit for alemtuzumab compared with no further therapy [38]. Alemtuzumab has limited effectiveness in bulky lymph nodal disease. Because of its toxicity profile, an increased risk for CMV infections, alemtuzumab is reserved for high risk and relapsed/refractory CLL. The role of alemtuzumab versus rituximab still remains unclear [38].

Multipronged Approach: Chemoimmunotherapy

The above three weapons were used in different combinations in the years to come. Each combination was compared to the gold standard that was set prior to that in superiority demonstrating randomized controlled studies (RCT). First F + rituximab (FR) was compared to F alone in a superiority trial. There were two arms in this study; patients were randomized to receive F for six cycles followed by R maintenance for four cycles sequentially or FR concurrently followed by R maintenance. Patients in the concurrent treatment arm had a higher ORR and CR rate (90 and 47 %, respectively) than those in the sequential treatment arm (77 and 28 %, respectively). Of note, patients in the sequential arm had not yet received rituximab upon evaluation of induction response, suggesting that the combination of rituximab and F was more effective than F alone [39]. Next F + C (FC) was compared to F + C + rituximab (FCR) in patients with good physical fitness and low cumulative illness rating scale. There was significantly higher CR (44.5 vs 22.9 %) and lower progressive disease (3.3 vs 8.1 %) in the FCR arm. This study established FCR as the standard first line from 2010 onwards [40]. The above two studies for the first time demonstrated survival advantage in CLL. The problem with FCR is that it has a significant toxicity profile and cannot be used in patients with significant comorbidities. In the search for less toxic combinations, bendamustine + rituximab (BR) was studied as first line. The overall response rates and CR rates were to the tune of 91 and 33 % respectively [41]. This was respectable in comparison to FCR which is the gold standard, where ORR was

95 % and CR was variable from 44 to 72 % [36, 42]. Ongoing RCTs are comparing BR and FCR as first line.

Hematopoietic Stem Cell Transplantation

Allogeneic SCT remains the only possible curative modality for CLL patients. Studies have demonstrated the existence of graft versus leukemia (GVL) effect in CLL [43]. Long term follow-up studies have shown durable CRs, nevertheless late relapses are known to occur [44]. Allogeneic SCT achieves long term DFS and possibly cure in one-third to two-third of the recipients. PFS and OS with allogeneic SCT is 36 % and 51 % at 5 years [45]. The choice between myeloablative and reduced intensity conditioning (RIC) needs to be balanced for transplant related mortality and relapse rates. Recent studies have shown that PFS and OS may be better in the RIC than myeloablative group due to the high nonrelapse related mortality in the myeloablative group [46]. The major indications for allogeneic SCT in CLL are summarized in Table 3.

Autologous HSCT

Autologous HSCT was compared to FCR in a RCT [48]. The event free and progression free survival were longer in patients receiving autologous SCT; however this did not translate into improved overall survival. It was concluded that the negative impact biomarkers like p53 aberrations that confer resistance to conventional therapy are not overcome by autografts. Currently autologous SCT for CLL cannot be justified outside of a clinical trial.

Tailored Approach

The treatment needs to be tailored according to the disease and patient factors. Asymptomatic patients in Binet A and B must not be treated outside of a clinical trial. Disease related factors include risk assessment according to various prognostic markers. Particularly 17p deletion necessitates more aggressive management. Patient related factors include tolerability depending on age, comorbidities and performance status. Depending on this patients can be categorized into three groups (Table 4). The “green group” includes patients who have good clinical status defined by good performance status (PS < 2) and have no

Table 3 EBMT CLL transplantation consensus criteria [47]

1 Patients with de novo deletion 17p13 or p53 mutation requiring treatment
2 Relapse within 24 months of chemoimmunotherapy
3 Non response or relapse within 12 months of purine based chemotherapy

Table 4 Current management approach for treatment naive CLL

Group status	Treatment options	Treatment regimen	OR %	CR %	PFS months
Non high risk Good clinical status	FCR (51)	F 25 mg/m ² x 3 days C 250 mg/m ² x 3 days R 375 mg/m ² day 0 cycle 1 & 500 mg/m ² day 1 cycle 2–6	95	44	52
	BR (52)	B 90 mg/m ² days 1 and 2 R 375 mg/m ² day 0 cycle 1 & 500 mg/m ² day 1 cycle 2–6	91	33	NR
	FR (53)	F 25 mg/m ² x 5 days R 375 mg/m ² day 1 & 4 cycle 1 375 mg/m ² day 1 cycle 2–6	90	47	42
Non High risk Poor clinical status	Chlorambucil (54)	Cl 0.8 mg/kg day 1 and day 15	48	3	8.3
	Bendamustine (52)	B 100 mg/m ² day 1 and 2	68	31	21.6
	FCR lite (55)	R 375 mg/m ² day 1, 500 mg/m ² day 14 cycle 1 500 mg/m ² day 1 & 14 cycles 2–6 F 20 mg/m ² x 3 days C 150 mg/m ² x 3 days	100	77	NA
	Rituximab+ Chlorambucil (56)	R 375 mg/m ² day 1, cycle 1 500 mg/m ² day 1 cycles 2–6 Cl 10 mg/m ² /day x 7 days	82	9	NA
High risk	Alemtuzumab (57) + SCT	10 mg sc thrice a week x 12 weeks followed by Allogeneic SCT	40	7	10.7

OR overall response, CR complete response, PFS progression free survival, NR not reached, NA not available

comorbidities. The goal in such group of patients is cure with longer remissions using more intensive therapies. The other “yellow group” includes patients with poor performance status and have comorbidities. Here the goal is disease control with less intensive therapies. The first line standard for patients in “green group” is FCR. However BR and FR are acceptable alternatives. For patients in “yellow group” chlorambucil is still an option. Other options in this group include bendamustine alone, chlorambucil + rituximab or dose reduced FCR (FCR lite) [49]. The “red group” includes patients with high risk CLL (del17p). Young patients with good clinical status in this group are candidates for allogeneic SCT following induction therapy, if a suitable donor is available. Patients with poor clinical status in this group are candidates for experimental therapy [50].

Drugs for Relapsed/Refractory CLL

Disease refractoriness was traditionally described in terms of F refractory CLL. CLL, non responding or relapsing within 6 months of F was included in this group. However it was seen that even relapses up to 36 months fared poorly and this accounted for one-third of all treated patients. So the definition of treatment resistant CLL has been expanded to include late relapses also. It was the need of the hour

to develop drugs with different mechanisms of action for relapsed/refractory CLL.

Lenalidomide, an immunomodulator, after its success in multiple myeloma was tried in CLL. Lenalidomide has multiple effects on modulation of T cell function in CLL [58]. It causes upregulation of CD40L resulting in increased T cell proliferation and production of Th1 cytokines. Increased expression of CD40, CD80 and CD86 leads to improved CLL B-cell antigen presentation. Repair of actin cytoskeletal signaling is associated with improved immunological synapse formation and effector CD8 T cell activity. Although lenalidomide has shown some activity in CLL, it has significant dose limiting toxicity and poor patient tolerability [59].

Ofatumumab targets a different epitope on CD20 than rituximab. It is generated by hybridoma technique. It has a slower off-rate, which might result in increased effectiveness in initiating complement-dependent cytotoxicity. Ofatumumab shows greater in vitro activity against CLL cells than rituximab, and is able to lyse rituximab-resistant cells that express low levels of CD20. It received FDA approval in 2009. Two doses of ofatumumab 500 and 1,000 mg were compared in combination with FC. It was seen that the CR rates were (50 vs. 35 %) in favor of higher dose, but at the cost of significant higher grade 3/4 neutropenia and infections [60].

Table 5 Current management approach for early relapsed/refractory CLL

Group status	Treatment options	Treatment regimen	OR %	OS months	PFS months
Non high risk Good clinical status	FCR (65)	F 25 mg/m ² C 250 mg/m ² x 3 days R 375 mg/m ² day 0 cycle 1 & 500 mg/m ² day 1 cycle 2–6	56	38	8
	Alemtuzumab (66)	30 mg sc 3 times a week x 12 weeks	34	19.1	7.7
	Lenalidomide (67)	10 mg/day	25	NR	12
Non High risk Poor clinical status	BR (68)	B 70 mg/m ² days 1 and 2 R 375 mg/m ² day 0 cycle 1 & 500 mg/m ² day 1 cycle 2–6	59	9	14.7
High risk	Alemtuzumab+ HDD (69)	Dex 40 mg x 4 days every 14 days 30 mg sc 3 times a week x 12 weeks	51	-	-
	R + HDMP (70)	HDMP 1gm/m ² x 5 days every 28 days R 375 mg/m ² weekly x 4 weeks	91	-	-

HDD high dose dexamethasone, HDMP high dose methylprednisolone, OR overall response, OS overall survival, PFS progression free survival, NR not reached

GA101

This is the first humanized and glycol-engineered type2 monoclonal anti CD20 antibody. It shows increased ADCC and apoptosis compared to rituximab. In a phase 1 study of 13 patients with poor risk cytogenetics and relapsed/refractory CLL, the overall response rates were 62 % [61].

B Cell Receptor Inhibitors

CAL-101 is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) signaling. In phase 1 studies it had nodal response rates of 80 %. However, it paradoxically caused peripheral blood lymphocytosis by causing compartmental shift from the tissue microenvironment [62]. Brutons tyrosine kinase inhibitor PCI32765 has nodal response rates of 87 % and has demonstrated promising clinical activity in CLL [63].

Flavopiridol is a synthetic flavone that inhibits cyclin dependent kinase CDK1, 2 and 9. It has shown some promise in poor prognostic population but has considerable toxicity [64].

Treatment Approach for Relapsed/Refractory CLL (Table 5)

Repeat testing for del17p should be done in all such relapsed patients. Patients relapsing early i.e. within 1 year of purine based chemotherapy or within 2 years of chemo-immunotherapy within the “green group” should be started on non cross resistant regimens like FCR or novel drugs like

alemtuzumab, lenalidomide, ofatumomab or included in clinical trials. BR is an option for patients in the “yellow group”. Alemtuzumab is avoided if the disease is bulky F refractory (BFR). The mechanism of glucocorticoids is p53 independent. Hence combinations of high dose steroids and alemtuzumab/rituximab have been found to be effective in the “red group”. Young patients with matched sibling donor should be considered for allogeneic SCT following remission induction. For late relapses, patients can be treated with the same or a different first line chemoimmunotherapy.

Minimal Residual Disease

Analogous to other leukemias, achievement of MRD negative remissions has been studied in CLL. It has been seen that patients with MRD negativity at the end of chemotherapy have higher PFS and OS in comparison to patients not achieving MRD. The method of assessing MRD is critical. The methods with better sensitivity include Flow MRD and Allele specific PCR. Alemtuzumab consolidation for 6–16 weeks has achieved MRD negativity varying from 20 to 56 % [70, 71]. Other drugs that are being tried as consolidation strategies to eradicate MRD include rituximab, lenalidomide. Currently consolidation is not recommended outside of a clinical trial.

CARS for Cure

Chimeric antigen receptor modified autologous T cells (CARs) are designer T-cells with specificity for CD19 coupled with CD137 (Costimulatory receptor) and

CD3-zeta signaling domain transduced with lentiviral vectors. When these were infused in 3 CLL patients as a part of phase I study, the results were astonishing with no evidence of adenopathy or disease in the bone marrow at 28 days. There was ongoing remission at 10 months of the study [72]. The advantage of CARs lies in the HLA independent antigen recognition making them broadly applicable [73]. There have been studies showing the application of such engineered T-cells for adoptive T-cell transfer therapy in other diseases [74]. Until similar studies with long term follow-up are available, such therapies will be restricted to the realm of clinical trials.

The final word is that both the origins and cure of CLL has eluded the human race. CLL remains an incurable disease outside allogeneic stem cell transplantation, which has its own complications. Biology and therapeutics go hand in hand. As our understanding of the disease biology progresses, we might find clues to conquer this disease ultimately. Similar to the targeted therapies that have worked wonders in chronic myeloid leukemia and acute promyelocytic leukemia the future of CLL lies in immunotherapy [75] and molecular targeted therapies. A combined multimodality approach might see us achieving our ultimate goal in CLL.

References

- Caligaris Cappio F (2009) Chronic lymphocytic leukemia: cinderella is becoming a star. *Mol Med* 15:67–69
- Klein U, Dalla Favera R (2010) New insights into the pathogenesis of chronic lymphocytic leukemia. *Semin Cancer Biol* 20:377–383
- Scarfò L, Dagklis A, Scielzo C, Fazi C, Ghia P (2010) CLL like monoclonal B-cell lymphocytosis: are we all bound to have it? *Cancer Biol* 20:384–390
- Kem W, Bacher U, Haferlach C, Dicker F et al (2012) Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukemia and may be better classified as early stage CLL. *Br J Haematol* 157:86–96
- Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. *N Engl J Med* 352:804–815
- Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. *Blood* 114:3367–3375
- Packham G, Stevenson S (2010) The role of B-cell receptor in the pathogenesis of chronic lymphocytic leukemia. *Semin Cancer Biol* 20:391–399
- Pederson IM, Reed JC (2004) Microenvironmental interactions and survival of CLL B-cells. *Leuk Lymphoma* 45:2365–2372
- Herishanu Y, Perez-Galan P, Liu D et al (2011) The lymph-node microenvironment promotes B-cell receptor signaling, NF- κ B activation, and tumor proliferation in chronic lymphocytic leukemia. *Blood* 117:563–574
- Furman RR (2010) Prognostic markers and stratification of chronic lymphocytic leukemia. *Hematology* 2010:77–81
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. *Blood* 46:219–234
- Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer* 48:198–206
- Hodgson K, Ferrer G, Montserrat E, Moreno C (2011) Chronic lymphocytic leukemia and autoimmunity: a systematic review. *Haematologica* 96:752–761
- Molica S, Alberti A (1987) Prognostic value of lymphocyte doubling time in CLL. *Cancer* 60:2712–2716
- Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F (2009) Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. *Haematologica* 94:887–888
- Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 343:1910–1916
- Oscier DG, Gardiner AC, Mould SJ et al (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. *Blood* 100:1177–1184
- Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 94:1848–1854
- Orchard JA, Ibbotson RE, Davis Z et al (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. *Lancet* 363:105–111
- Crespo M, Bosch F, Villamor N et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. *N Engl J Med* 348:1764–1775
- Varma S, Lad D, Varma N, Sachdeva MUS, Bose P, Malhotra P (2011) Do regulatory T cells have a role in disease progression and autoimmune cytopenias of chronic lymphocytic leukemia? (Abstract). *Blood* 118:3864
- Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. *Blood* 111:5446–5456
- Altman SJ, Haut A, Cartwright GE, Wintrobe MM (1956) Early experience with p-(N,N-D1-2-chloroethyl) aminophenylbutyric acid (CB1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia. *Cancer* 9:512–517
- No authors cited (1999) Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. *J Natl Cancer Inst* 91:861–868
- Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol* 27:4378–4384
- Rai KR, Peterson BL, Appelbaum FR et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *N Engl J Med* 343:1750–1757
- Rai KR, Hollweg A (2011) Fludarabine versus chlorambucil: is the debate over? *Clin Lymphoma Myeloma Leuk* 11:S7–S9
- Eichhorst BF, Busch R, Stilgenbauer S et al (2009) First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. *Blood* 114:3382–3391
- Eichhorst BF, Busch R, Hopfinger G et al (2006) German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. *Blood* 107:885–891
- Richards S, Steurer M, for the CLLTCG CLL Trialists Collaborative Group, UK (2012) Systematic review of purine analogue treatment for chronic lymphocytic leukemia: lessons for future trials. *Haematologica* 97:428–3696

31. McLaughlin P, Grillo-López AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncol* 16:2825–2833
32. Itälä M, Geisler CH, Kimby E et al (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. *Eur J Haematol* 69:129–134
33. Hainsworth JD, Litchy S, Barton JH et al (2003) Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. *J Clin Oncol* 21:1746–1751
34. Osterborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. *J Clin Oncol* 15:1567–1574
35. Rai KR, Freter CE, Mercier RJ et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. *J Clin Oncol* 20:3891–3897
36. Osterborg A, Mellstedt H, Keating M (2002) Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. *Med Oncol* 19:S21–S26
37. Lundin J, Kimby E, Björkholm M et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). *Blood* 100:768–773
38. Skoetz N, Bauer K, Elter T et al (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. *Cochrane Database Syst Rev* 2:CD008078
39. Byrd JC, Peterson BL, Morrison VA et al (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). *Blood* 101:6–14
40. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial. *Lancet* 376:1164–1174
41. Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol* 29:3559–3566
42. Tam CS, Keating MJ (2010) Chemoimmunotherapy of chronic lymphocytic leukemia. *Nat Rev Clin Oncol* 7:521–532
43. Schetelig J, Thiede C, Bornhauser M et al (2003) Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. *J Clin Oncol* 21:2747–2753
44. Malhotra P, Hogan WJ, Litzow MR et al (2008) Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. *Leuk Lymphoma* 49:1724–1730
45. Sorror ML, Storer BE, Sandmaier BM et al (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. *J Clin Oncol* 26:4912–4920
46. Brown JR, Stevenson K, Kim HT et al (2008) Comparative outcome of myeloablative and reduced intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia. *Blood* 112:972
47. Dreger P, Corradini P, Kimby E et al (2007) Chronic leukemia working party of the EBMT. Indications for Allogeneic stem cell transplantation in CLL: the EBMT transplant consensus. *Leukemia* 21:12–17
48. Sutton L, Chevret S, Tournilhac O et al (2011) Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. *Blood* 117:6109–6119
49. Del Giudice I, Mauro FR, Foà R (2011) Chronic lymphocytic leukemia in less fit patients “slow-go”. *Leuk Lymphoma* 52:2207–2216
50. Zent CS, Kay NE (2011) Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. *Leuk Lymphoma* 52:1425–1434
51. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of Rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open label, phase 3 trial. *Lancet* 376:1164–1174
52. Fischer K, Cramer P, Stilgenbauer S et al (2009) Bendamustine combined with rituximab (BR) in first line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study group (GCLLSG) (Abstract). *Blood* 114:89
53. Woyach JA, Ruppert AS, Heerema NA et al (2011) Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. *J Clin Oncol* 29:1349–1355
54. Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. *Blood* 114:3382–3391
55. Foon KA, Boyiadzis M, Land SR et al (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol* 27:498–503
56. Hillmen P, Gribben JG, Follows GA et al (2010) Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study (Abstract). *Blood* 116:697
57. Pitini V, Arrigo C, Naro C et al (2008) Subcutaneous low-dose alemtuzumab as first linetherapy for elderly CLL patients with deletion of 17p. *J Clin Oncol* 26:384s
58. Riches JC, Ramsay AG, Gribben JG (2010) T-cell function in chronic lymphocytic leukaemia. *Semin Cancer Biol* 20:431–438
59. Wendtner C, Hillmen P, Mahadevan D et al (2012) Final results of the phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 Study). *Leuk Lymphoma* 53:417–423
60. Wierda WG, Kipps TJ, Dürig J et al (2011) Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. *Blood* 117:6450–6458
61. Morschhauser F, Cartron G, Lamy T et al (2009) Phase I study of RO5072759 (GA101) in relapsed/refractory CLL (Abstract). *Blood* 114:364
62. Furmann RR, Byrd JC, Brown JR et al (2010) CAL-101, an isoform selective inhibitor of phosphatidylinositol 3-kinase P110 δ , demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory CLL (Abstract). *Blood* 116:31
63. Burger JA, O'Brien S, Fowler N et al (2010) The Brutons tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in CLL and SLL: an update on ongoing phase I studies (Abstract). *Blood* 116:32

64. Lanasa MC, Andritsos L, Brown JR et al (2010) Interim analysis of EFC6663, a multicenter phase 2 study of Alvocidib (Flavopiridol), demonstrates clinical responses among patients with Fludarabine refractory CLL (Abstract). *Blood* 116:32
65. Badoux XC, Keating MJ, Wang X et al (2011) Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective for relapsed patients with CLL. *Blood* 117:3016–3024
66. Stigenbauer S, Zenz T, Winkler D et al (2009) Subcutaneous alemtuzumab in fludarabine refractory chronic lymphocytic leukemia: clinical results and prognostic marker analysis from the CLL2H study of the German CLL study group. *J Clin Oncol* 27:3994–4001
67. Ferrajoli A, Lee BN, Scllette EJ et al (2008) Lenalidomide induces complete and partial remissions in with relapsed and refractory CLL. *Blood* 111:5291–5297
68. Stilgenbauer S, Cymbalista F, Leblond V et al (2010) Subcutaneous Alemtuzumab combined with oral Dexamethasone, followed by Alemtuzumab maintenance or Allo-SCT in CLL with 17p or refractory to fludarabine: interim analysis of the CLL 20 trial of the GCLLSG and FCCLL/MW (Abstract). *Blood* 116:920
69. Castro JE, Sandoal-Sus JD, Bole J, Rassenti L, Kipps TJ (2008) Rituximab in combination with high dose methylprednisolone for the treatment of fludarabine refractory high risk chronic lymphocytic leukemia. *Leukemia* 22:2048–2053
70. Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell CLL after Alemtuzumab therapy is associated with prolonged survival. *J Clin Oncol* 23: 2971–2979
71. Wendtner CM, Ritgen M, Schweighofer CD et al (2004) Consolidation with alemtuzumab in patients with CLL in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG). *Leukemia* 18:1093–1101
72. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor: modified T-cells in chronic lymphocytic leukemia. *N Engl J Med* 365:725–733
73. Sadelain M, Brentjens R, Riviere (2009) The promise and pitfalls of chimeric antigen receptors. *Curr Opin Immunol* 21:215–223
74. June Ch, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. *Nat Rev Immunol* 9: 704–716
75. Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy: revisited. *Nat Rev Drug Dis* 10:591–600